The relationship between pre-radiation therapy testosterone levels and prostate cancer aggressiveness.
Gleason
PSA
prostate cancer
testosterone
Journal
Andrologia
ISSN: 1439-0272
Titre abrégé: Andrologia
Pays: Germany
ID NLM: 0423506
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
23
04
2020
revised:
28
05
2020
accepted:
03
06
2020
pubmed:
7
7
2020
medline:
22
6
2021
entrez:
7
7
2020
Statut:
ppublish
Résumé
We investigated whether there is an association between testosterone levels and prostate cancer aggressiveness in patients treated with radiation therapy who underwent a prostatectomy or prostate radiotherapy (EBRT). A total of 380 patients who received primary or post-operative radiotherapy were identified. At the time of radiotherapy, baseline testosterone levels and body mass index (BMI) measurements were available. On multivariate analysis (MVA), higher prostate-specific antigen (PSA) levels were predictive of testosterone ≥10.4 (OR = 1.3, p = .04) and testosterone ≥12.0 nmol/L (OR = 1.3, p = .04). Patients with a Gleason score ≥8 were more likely to have testosterone <8 nmol/L than patients with a lower score (31% vs. 20%, p = .043). On univariate analysis, a Gleason score ≥8 was associated with a lower likelihood of having a normal (≥8 nmol/L) testosterone level (OR = 0.51, 95% CI: 0.3-0.9, p = .02), and on MVA adjusted for post-surgical versus primary EBRT and BMI (≥30 kg/m
Substances chimiques
Testosterone
3XMK78S47O
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13731Informations de copyright
© 2020 Blackwell Verlag GmbH.
Références
Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., … McKinlay, J. B. (2007). Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology and Metabolism, 92(11), 4241-4247. https://doi.org/10.1210/jc.2007-1245
Araujo, A. B., O’Donnell, A. B., Brambilla, D. J., Simpson, W. B., Longcope, C., Matsumoto, A. M., & McKinlay, J. B. (2004). Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism, 89, 5920-5926. https://doi.org/10.1210/jc.2003-031719
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010). Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 95(6), 2536-2559. https://doi.org/10.1210/jc.2009-2354
Claps, M., Petrelli, F., Caffo, O., Amoroso, V., Roca, E., Mosca, A., … Berruti, A. (2018). Testosterone levels and prostate cancer prognosis: A systematic review and meta-analysis. Clinical Genitourinary Cancer 16, 165-175.
Cooperberg, M. R., Pasta, D. J., Elkin, E. P., Litwin, M. S., Latini, D. M., Du Chane, J., & Carroll, P. R. (2005). The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. The Journal of Urology, 173(6), 1938-1942. https://doi.org/10.1097/01.ju.0000158155.33890.e7
Daniell, H. W., Clark, J. C., Pereira, S. E., Niazi, Z. A., Ferguson, D. W., Dunn, S. R., … Stratte, P. T. (2001). Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer, 91(10), 1889-1895. https://doi.org/10.1002/1097-0142(20010515)91:10<1889:AID-CNCR1211>3.0.CO;2-U
Eriksson, J., Haring, R., Grarup, N., Vandenput, L., Wallaschofski, H., Lorentzen, E., … Ohlsson, C. (2017). Causal relationship between obesity and serum testosterone status in men: A bi-directional mendelian randomization analysis. PLoS One, 12(4), e0176277. https://doi.org/10.1371/journal.pone.0176277
Gacci, M., Tosi, N., Vittori, G., Minervini, A., Corona, G., Cai, T., … Carini, M. (2013). Changes in sex hormone levels after radical prostatectomy: Results of a longitudinal cohort study. Oncology Letters, 6(2), 529-533. https://doi.org/10.3892/ol.2013.1420
Ji, Q., Chang, L., Stanczyk, F. Z., Ookhtens, M., Sherrod, A., & Stolz, A. (2007). Impaired dihydrotestosterone catabolism in human prostate cancer: Critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Research, 67(3), 1361-1369. https://doi.org/10.1158/0008-5472.CAN-06-1593
Kacker, R., Morgentaler, A., & Traish, A. (2014). Medical hypothesis: Loss of the endocrine function of the prostate is important to the pathophysiology of postprostatectomy erectile dysfunction. The Journal of Sexual Medicine, 11(8), 1898-1902. https://doi.org/10.1111/jsm.12574
Khera, M., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., … Salonia, A. (2016). Diagnosis and treatment of testosterone deficiency: Recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). The Journal of Sexual Medicine, 13(12), 1787-1804.
Lackner, J. E., Maerk, I., Koller, A., Bieglmayer, C., Marberger, M., Kratzik, C., & Schatzl, G. (2008). Serum inhibin-not a cause of low testosterone levels in hypogonadal prostate cancer? Urology, 72(5), 1121-1124. https://doi.org/10.1016/j.urology.2008.01.066
Loeb, S., Folkvaljon, Y., Damber, J.-E., Alukal, J., Lambe, M., & Stattin, P. (2017). Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. Journal of Clinical Oncology, 35(13), 1430. https://doi.org/10.1200/JCO.2016.69.5304
Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S., Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015). Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The Aging Male, 18(1), 5-15. https://doi.org/10.3109/13685538.2015.1004049
Madersbacher, S., Schatzl, G., Bieglmayer, C., Reiter, W. J., Gassner, C., Berger, P., … Marberger, M. (2002). Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology, 60(5), 869-874. https://doi.org/10.1016/S0090-4295(02)01893-9
Mahal, B. A., Yang, D. D., Wang, N. Q., Alshalalfa, M., Davicioni, E., Choeurng, V., … Nguyen, P. L. (2018). Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. European Urology, 74(2), 146-154. https://doi.org/10.1016/j.eururo.2018.01.043
Miller, L. R., Partin, A. W., Chan, D. W., Bruzek, D. J., Dobs, A. S., Epstein, J. I., & Walsh, P. C. (1998). Influence of radical prostatectomy on serum hormone levels. The Journal of Urology, 160(2), 449-453. https://doi.org/10.1016/S0022-5347(01)62922-7
Morgentaler, A., & Traish, A. M. (2009). Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. European Urology, 55(2), 310-321. https://doi.org/10.1016/j.eururo.2008.09.024
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., … Lewis, R. W. (2018). Evaluation and management of testosterone deficiency: AUA guideline. The Journal of Urology, 200(2), 423-432. https://doi.org/10.1016/j.juro.2018.03.115
Nishiyama, T., Ikarashi, T., Hashimoto, Y., Wako, K., & Takahashi, K. (2007). The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. The Journal of Urology, 178(4), 1282-1289. https://doi.org/10.1016/j.juro.2007.05.138
Olsson, M., Ekström, L., Schulze, J., Kjellman, A., Akre, O., Rane, A., & Gustafsson, O. (2010). Radical prostatectomy: Influence on serum and urinary androgen levels. The Prostate, 70(2), 200-205.
Pompe, R. S., Karakiewicz, P. I., Zaffuto, E., Smith, A., Bandini, M., Marchioni, M., … Taussky, D. (2017). External beam radiotherapy affects serum testosterone in patients with localized prostate cancer. The Journal of Sexual Medicine, 14(7), 876-882. https://doi.org/10.1016/j.jsxm.2017.04.675
Schatzl, G., Madersbacher, S., Thurridl, T., Waldmüller, J., Kramer, G., Haitel, A., & Marberger, M. (2001). High-grade prostate cancer is associated with low serum testosterone levels. The Prostate, 47(1), 52-58. https://doi.org/10.1002/pros.1046
Takizawa, I., Nishiyama, T., Hara, N., Isahaya, E., Hoshii, T., & Takahashi, K. (2010). Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. The Prostate, 70(13), 1395-1401. https://doi.org/10.1002/pros.21174
van der Sluis, T. M., Meuleman, E. J., van Moorselaar, R. J. A., Bui, H. N., Blankenstein, M. A., Heijboer, A. C., & Vis, A. N. (2012). Intraprostatic testosterone and dihydrotestosterone. Part II: Concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU International, 109(2), 183-188.
Wallerstedt, A., Strom, P., Gronberg, H., Nordstrom, T., & Eklund, M. (2018). Risk of prostate cancer in men treated with 5α-reductase inhibitors-a large population-based prospective study. JNCI: Journal of the National Cancer Institute, 110(11), 1216-1221. https://doi.org/10.1093/jnci/djy036
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., … Wu, F. C. W. (2009). ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research, 21(1), 1-8. https://doi.org/10.1038/ijir.2008.41
Zarotsky, V., Huang, M. Y., Carman, W., Morgentaler, A., Singhal, P., Coffin, D., & Jones, T. (2014). Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology, 2(6), 819-834. https://doi.org/10.1111/andr.274